

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 01/26/2016 | ·[Baxter](http://www.fda.gov/Safety/Recalls/ucm483147.htm)   | ·0.9% Sodium Chloride Injection, Metronidazole Injection, and Clinimix E 5/15   | ·Leaking containers and particulate matter | ·Baxter International Inc. |
| 01/20/2016 | ·[Master Herbs, Inc.](http://www.fda.gov/Safety/Recalls/ucm482524.htm)   | ·Licorice Coughing Liquid   | ·Contains undeclared morphine | ·Master Herbs, Inc. |
| 01/16/2016 | ·[Abbott's Compounding Pharmacy](http://www.fda.gov/Safety/Recalls/ucm482101.htm)   | ·Sterile Compounded Products that include injectable medications, sterile solutions, eye drops, and eye ointments   | ·Lack of Sterility Assurance | ·Abbott's Compounding Pharmacy |

**SHORTAGESFebruary 16, 2016**

[Valsartan and Hydrochlorothiazide Tablet, Film Coated](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Valsartan%20and%20Hydrochlorothiazide%20Tablet,%20Film%20Coated&st=d&tab=tabs-4) (***Discontinuation***)

* [Valsartan Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Valsartan%20Tablets&st=d&tab=tabs-4) (***Discontinuation***)

·**February 12, 2016**

* [Memantine Hydrochloride (Namenda) Unit Dose XR Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Memantine%20Hydrochloride%20%28Namenda%29%20Unit%20Dose%20XR%20Capsules%20&st=d&tab=tabs-4) (***Discontinuation***)

·**February 05, 2016**

* [Sodium Bicarbonate Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection,%20USP&st=c&tab=tabs-4) (***Currently in Shortage***)

·**February 04, 2016**

* [Sodium Bicarbonate Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection,%20USP&st=c&tab=tabs-4) (***Currently in Shortage***)

·**February 03, 2016**

* [Potassium Acetate Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Potassium%20Acetate%20Injection,%20USP&st=c&tab=tabs-4) (***Currently in Shortage***)
* [Sodium Acetate Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Acetate%20Injection,%20USP&st=c&tab=tabs-4) (***Currently in Shortage***)

·**Updated**

·**February 16, 2016**

* [Azathioprine Tablet](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Azathioprine%20Tablet&st=r&tab=tabs-4)   (***Resolved***)

·**February 12, 2016**

* [Levetiracetam (Keppra) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Levetiracetam%20%28Keppra%29%20Injection&st=r&tab=tabs-4)   (***Resolved***)

·**February 11, 2016**

* [Memantine Hydrochloride (Namenda) XR Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Memantine%20Hydrochloride%20%28Namenda%29%20XR%20Capsules&st=r&tab=tabs-4)   (***Resolved***)

·**February 10, 2016**

* [Cefepime Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cefepime%20Injection&st=c&tab=tabs-4)   (***Currently in Shortage***)
* [Imipenem and Cilastatin for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Imipenem%20and%20Cilastatin%20for%20Injection,%20USP&st=c&tab=tabs-4)   (***Currently in Shortage***)
* [Meropenem for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Meropenem%20for%20Injection,%20USP&st=c&tab=tabs-4)   (***Currently in Shortage***)
* [Potassium Chloride Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Potassium%20Chloride%20Injection&st=c&tab=tabs-4)   (***Currently in Shortage***)

·**February 08, 2016**

* [Desmopressin Acetate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Desmopressin%20Acetate%20Injection&st=c&tab=tabs-4)   (***Currently in Shortage***)

**MedWatch: The FDA Safety Information and Adverse Event Reporting Program**

·[January 2016](http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm485289.htm) Drug Safety Labeling Changes includes 26 products with revisions to Prescribing Information. Posted 02/12/2015

·[Central Venous Catheters and Pressure Monitoring Sets and Trays by Cook Medical: Recall - Catheter Tip Fracture and/or Separation](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm485910.htm) Risk of stroke, kidney injury, or damage to the intestines or limbs. Posted 02/11/2016

·[Syrspend SF and Syrspend SF Grape Suspending Agents by Fagron: FDA Alert - Microbial Contamination with Yeast](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm485897.htm) If an immunocompromised patient or a child with an immature immune system ingests the contaminated product, there is a potential the patient will get an infection for which systemic antimicrobial therapy would be necessary. Posted 02/10/2016

·[Oxylog 2000 Plus, 3000, and 3000 Plus Emergency Transport Ventilators by Dräger Medical: Class I Recall - System Error May Lead to a Halt in Ventilation Therapy](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm485807.htm) If the device operator does not intervene, the patient may not receive enough oxygen and could suffer serious adverse health consequences, including injury or death. Posted 02/10/2016

**FDA approves Aurobindo’s generic Vfend**

·[**http://www.drugstorenews.com/article/fda-approves-aurobindos-generic-vfend**](http://www.drugstorenews.com/article/fda-approves-aurobindos-generic-vfend)

**FDA Approves Two Sumatriptan Treatments for Migraine**

·[**http://www.neurologyadvisor.com/headache/fda-approves-two-sumatriptan-treatments-for-migraine/article/473624/?DCMP=EMC-Neuro\_Update&cpn=&hmSubId=&hmEmail=zc9AEZF4x4rPbtLJAxJhmklDzcJVA8s10&NID=&dl=0&spMailingID=13729496&spUserID=NDgyNTEwMTE5NjYS1&spJobID=720920855&spReportId=NzIwOTIwODU1S0**](http://www.neurologyadvisor.com/headache/fda-approves-two-sumatriptan-treatments-for-migraine/article/473624/?DCMP=EMC-Neuro_Update&cpn=&hmSubId=&hmEmail=zc9AEZF4x4rPbtLJAxJhmklDzcJVA8s10&NID=&dl=0&spMailingID=13729496&spUserID=NDgyNTEwMTE5NjYS1&spJobID=720920855&spReportId=NzIwOTIwODU1S0)

**FDA Enforcement Report**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ·Drugs | ·[Lyrica (pregabalin) capsules, 50 mg, 90-count bottle, Rx only, Distributed by: Parke-Davis, Division of Pfizer Inc., NY, NY 10017, NDC 0071-1013-68](http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0648-2016&w=02102016&lang=eng) | ·Lot #: M07861, Exp 05/2018  | ·Class II | ·FAILED TABLET/CAPSULE SPECIFICATIONS: Firm is recalling specific lots of pregabalin capsules due to the potential presence of deformed or damaged capsules.  | ·Pfizer Inc. |
| ·Drugs | ·[Lyrica (pregabalin) capsules, 75 mg, 90-count bottle, Rx only, Distributed by: Parke-Davis, Division of Pfizer Inc., NY, NY 10017, NDC 0071-1014-68](http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0649-2016&w=02102016&lang=eng) | ·Lot #: M07862, Exp 05/2018; M07865, Exp 06/2018  | ·Class II | ·FAILED TABLET/CAPSULE SPECIFICATIONS: Firm is recalling specific lots of pregabalin capsules due to the potential presence of deformed or damaged capsules.  | ·Pfizer Inc. |
| ·Drugs | ·[Nystatin, USP Powder for Rx compounding, 50 Million Units, Packaged by Perrigo, Minneapolis MN 55427, NDC 0574-0405-05, UPC 305740404058.](http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0651-2016&w=02102016&lang=eng)  | ·Lot #: 2015050194, Exp 2/2016  | ·Class II | ·Labeling: label error on declared strength.  | ·Perrigo Company PLC |
| ·Drugs | ·[Nystatin, USP Powder for Rx compounding, 150 Million Units, Packaged by Perrigo, Minneapolis MN 55427, NDC 0574-0404-15, UPC 305740404157](http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0652-2016&w=02102016&lang=eng) | ·Lot #: 2015080484, Exp 02/2016  | ·Class II | ·Labeling: label error on declared strength.  | ·Perrigo Company PLC |
| ·Drugs | ·[Clonazepam Tablets, USP, 0.5 mg, 100-count carton, Rx only, Manufactured by Mylan Pharmaceuticals Inc., Morgantown, WV, 26505, NDC:51079-881-21](http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-0650-2016&w=02102016&lang=eng) | ·Lot # 3063759, Exp.07/16  | ·Class III | ·Failed Impurities/Degradation Specifications: out of specification result for known impurity at 6 month timepoint. | ·Mylan Institutional, Inc. (d.b.a. UDL Laboratories) |

**INSURANCE**·**Oklahoma Health Care Authority**

|  |  |  |
| --- | --- | --- |
| ·2016-04  | ·Prior Authorization of Medications Used to Treat Breast Cancer | ·2/3/2016 |
| ·2016-03  | ·Yearly Compliance with the Deficit Reduction Act of 2005 | ·1/28/2016 |
| ·2016-02  | ·Non-Invasive Prenatal Testing | ·1/6/2016 |
| ·2016-01  | ·Controlled Substance Monitoring and Drugs of Abuse Testing | ·1/5/2016 |

·**Express Scripts Drops Coverage of Valeant Diabetes Drug Glumetza**

o   <http://www.firstreportnow.com/articles/express-scripts-drops-coverage-valeant-diabetes-drug-glumetza>

·IMMUNIZATIONS

·[CDC's Health Alert Network publishes an advisory urging rapid antiviral treatment of very ill and high-risk suspect influenza patients without waiting for testing](https://us-mg4.mail.yahoo.com/neo/launch#IACX1)

o   <http://www.immunize.org/express/issue1227.asp>

·Clear Recommendations on Vaccination Are Important to Your Patients

o   <https://www.merckvaccines.com/FeaturedContent/Pages/home?article=Clear_Recommendations_Help_Get_Patients_Vaccinated>

**ADVERSE EFFECTS**

·**Antidepressant Effexor Linked to Postpartum Bleeding in Study**

o   [**https://www.nlm.nih.gov/medlineplus/news/fullstory\_157231.html**](https://www.nlm.nih.gov/medlineplus/news/fullstory_157231.html)

o**Pharmacist Education**

·**4 GERD Counseling Points for Pharmacists**

o   <http://www.pharmacytimes.com/resource-centers/acid-reflux/4-gerd-counseling-points-for-pharmacists?utm_source=Informz&utm_medium=Pharmacy+Times&utm_campaign=PT_eNews_Daily_Nexium_2-16-16>

·**In the Clinic: Metformin and Pancreatic Cancer**

o   <http://www.cancertherapyadvisor.com/pancreatic-cancer/pancreatic-cancer-metformin-lower-risk-treatment/article/470439/>

**NEWS**

·**5 Tips for Traveling to the U.S. With Medications**

o   [**http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm484154.htm**](http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm484154.htm)

·**Another STD Spurs Concern**

o   British study concludes Mycoplasma genitalium infection is transmitted through sexual contact

o   <https://www.nlm.nih.gov/medlineplus/news/fullstory_157233.html>

·**Greenstone launches Detrol LA authorized generic**

o   <http://www.drugstorenews.com/article/greenstone-launches-detrol-la-authorized-generic?utm_term=DSN204811&utm_source=MagnetMail&utm_medium=subject&utm_term=DSN%20Generics%20-%20Greenstone%20launches%20Detrol%20LA%20authorized%20generic&utm_content=DSN-NLE-Generics-2-3-16>

·**Encapsulated cells treat diabetes in mice**

o   <http://www.nih.gov/news-events/nih-research-matters/encapsulated-cells-treat-diabetes-mice>

·**Prepublication standards: check out Opioid Treatment Programs update, effective July 1**

o   <http://www.jointcommission.org/issues/article.aspx?Article=Rac5IS0DXr2%2bVsvXRxj%2b25U5UCQiPCIVtvzBNLQHK0E%3d&j=2801606&e=randygc2011@yahoo.com&l=9552_HTML&u=70596230&mid=1064717&jb=0>

·**Painkillers Don't Ease Disability Due to Nerve Damage: Study**

o   <https://www.nlm.nih.gov/medlineplus/news/fullstory_157017.html>

**ASTHMA**

·**Report Calls for New COPD, Asthma Treatment Methods**

o   <http://www.consultant360.com/exclusives/new-treatment-needed-copd-asthma-patients>